Lupus & Connective Tissue Diseases
Conference Coverage
Macitentan, tadalafil combo found effective for newly diagnosed PAH
Macitentan and tadalafil demonstrated efficacy in a phase 4 trial.
From the Journals
Low disease activity a valid target in early SLE, investigators say
Both lupus low disease activity state and complete remission by 6 months translated into less damage at 18 months in retrospective analysis.
Conference Coverage
Rituximab bests mycophenolate in pemphigus vulgaris
MADRID – “Rituximab has a superior overall benefit/risk profile, compared to mycophenolate mofetil, in patients with moderate to severe pemphigus...
From the Journals
Expanding Medicaid did not reduce preventable hospitalizations for lupus patients
SLE patients in four states that did expand Medicaid had higher odds for preventable lupus hospitalizations in comparison with four states that...
From the Journals
Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS
Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists.
Conference Coverage
Consider centralized pain in patients with rheumatic disease
LAS VEGAS – Every patient with chronic pain should complete a fibromyalgia survey, Dr. Daniel J. Clauw says.
From the Journals
White AAV patients post highest mortality rates
Age-adjusted AAV mortality declined overall, but was highest in non-Hispanic whites, men, and individuals in the Midwest.
From the Journals
Systemic sclerosis raises risk of breast cancer, lung cancer, melanoma
Patients with systemic sclerosis also had more than a doubling of the risk of mortality with incident cancer in comparison with systemic sclerosis...
Conference Coverage
Multicenter trial backs pirfenidone for unclassifiable interstitial lung disease
MADRID – Pirfenidone inhibits progression of unclassifiable interstitial lung disease in placebo-controlled trial.
From the Journals
Inflammatory arthritis induced by ICIs can persist after therapy
The study is “the first to evaluate persistence of ICI-induced IA and identify influential factors on outcome.”
Conference Coverage
TKI preserved lung function in patients with fibrosing interstitial disease
MADRID – The trial, called INBUILD, enrolled patients who had progressive lung...